Cellebrite DI Ltd. CLBT
12.70 USD +0.06 (+0.47%)
At closeNov 11, 2026, 5:37 PM EST
12.55 -0.15 -1.18%
After hours · Nov 11, 5:37 PM ET
12.58 Day range 12.89
9.58 52-week range 19.98
- YTD
- -29.56%
- 1 year
- -19.11%
News
prnewswire.com Cellebrite to Report Third-Quarter 2026 Financial Results on November 12, 2026 TYSONS CORNER, VA and PETAH TIKVA, ISRAEL, Nov. 9, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the…
prnewswire.com Cellebrite Appoints Rogerio Rizzi Executive Vice President of Corporate Strategy and Development Former Okta and SAP strategy leader brings AI, platform and M&A expertise to accelerate Cellebrite's growth TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 5, 2026 /PRNewswire/ -- Cellebrite…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellebrite DI Ltd. - CLBT NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ: CLBT).
prnewswire.com Genesis Momentum Powers Cellebrite's Autumn Release: More Evidence, Deeper Insight, Broader Access for Investigations Investigators report dramatic gains in what they uncover using Agentic AI vs. manual review; the Autumn 2026 Release brings expanded device and operating system access TYSONS CORNER, Va.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellebrite DI Ltd. – CLBT NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellebrite DI Ltd. (“Cellebrite” or the “Company”) (NASDAQ: CLBT). Such investors are advised…
prnewswire.com Cellebrite publiera ses résultats financiers du troisième trimestre 2026 le 12 novembre 2026 /PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ: CLBT), leader mondial des solutions numériques d'investigation et de renseignement basées sur l'IA pour les
prnewswire.com Cellebrite to Report Third-Quarter 2026 Financial Results on November 12, 2026 TYSONS CORNER, VA and PETAH TIKVA, ISRAEL, Oct. 20, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the…
defenseworld.net Cellebrite DI (NASDAQ:CLBT) CFO David Barter Sells 12,134 Shares of Company Stock Cellebrite DI Ltd. (NASDAQ: CLBT - Get Free Report) CFO David Barter sold 12,134 shares of Cellebrite DI stock in a transaction that occurred on Friday, October 16th. The shares were sold at an…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellebrite DI Ltd. - CLBT NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ: CLBT).
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellebrite DI Ltd. – CLBT NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellebrite DI Ltd. (“Cellebrite” or the “Company”) (NASDAQ: CLBT). Such investors are advised…
newsfilecorp.com Kaplan Fox Shareholder Alert: Cellebrite DI Ltd. (CLBT) is Under Investigation for Possible Securities Law Violations New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company")…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellebrite DI Ltd. - CLBT NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ: CLBT).
newsfilecorp.com Kaplan Fox is Investigating Cellebrite DI Ltd. (CLBT) for Investors Who Suffered Losses New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company")…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellebrite DI Ltd. – CLBT NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellebrite DI Ltd. (“Cellebrite” or the “Company”) (NASDAQ: CLBT). Such investors are advised…
newsfilecorp.com CLBT INVESTIGATION: Cellebrite Investigated by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses Boston, Massachusetts--(Newsfile Corp. - October 2, 2026) - Block & Leviton is investigating Cellebrite DI (NASDAQ: CLBT) for potential securities law violations. Investors who have lost money in…
newsfilecorp.com Kaplan Fox Urges Investors of Cellebrite DI Ltd. (CLBT) with Losses to Contact the Firm New York, New York--(Newsfile Corp. - October 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company")…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellebrite DI Ltd. - CLBT NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ: CLBT).
newsfilecorp.com Kaplan Fox Reminds Investors of Cellebrite DI Ltd. (CLBT) of an Ongoing Securities Investigation New York, New York--(Newsfile Corp. - September 30, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company")…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellebrite DI Ltd. – CLBT NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellebrite DI Ltd. (“Cellebrite” or the “Company”) (NASDAQ: CLBT). Such investors are advised…
fool.com Cellebrite's 2026 Outlook: Subscription Pivot Weighs on the Stock Today, Helps Lead a Future Rebound Cellebrite maintains a strong competitive moat through deep integration with government and law enforcement. Recent guidance resets and CEO turnover highlight execution risks for the software pivot.
benzinga.com Lake Street Maintains Buy on Cellebrite DI, Lowers Price Target to $15 Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $21 to $15.
benzinga.com JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16 JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $20 to $16.- benzinga.com DA Davidson Maintains Buy on Cellebrite DI, Lowers Price Target to $15 DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $22 to $15.
benzinga.com Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5 Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.
benzinga.com 12 Information Technology Stocks Moving In Thursday's Intraday Session Gainers BGIN Blockchain (NASDAQ:BGIN) stock rose 38.8% to $2.36 during Thursday's regular session. The company's market cap stands at $192.3 million. Iveda Solutions (NASDAQ:IVDA) shares moved…
benzinga.com Cellebrite Shares Plunge Thursday: What's Driving the Move? Shares of Cellebrite are trading sharply lower on Thursday following the release of second-quarter financial results that missed top-line expectations alongside downgraded revenue guidance for the…
benzinga.com Gold Down 2%; Cisco Shares Tumble After Q4 Results US stocks mixed, Nasdaq up more than 150 points. Dow down 0.16% to 53,682.87, Nasdaq up 0.61% to 26,749.51, S&P 500 up 0.45% to 7,783.09. Real estate sector up 1.2%, energy down 1%. Cisco shares down…
benzinga.com Full Transcript: Cellebrite DI Q2 2026 Earnings Call Cellebrite DI (NASDAQ:CLBT) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought…
benzinga.com Dow Gains Over 100 Points; Producer Prices Unchanged In July US stocks up, Dow gains over 100 points. Real estate sector rises, energy sector falls. Producer Price Index unchanged, inflation rate down.
benzinga.com 12 Information Technology Stocks Moving In Thursday's Pre-Market Session Gainers Yxt.Com Group Holding (NASDAQ:YXT) stock moved upwards by 47.5% to $6.68 during Thursday's pre-market session. The company's market cap stands at $27.6 million. As per the press release, H1…
benzinga.com Cellebrite DI Lowers FY2026 Sales Guidance from $565.000M-$571.000M to $555.000M-$561.000M vs $568.048M Est Cellebrite DI (NASDAQ:CLBT) lowers FY2026 sales outlook from $565.000 million-$571.000 million to $555.000 million-$561.000 million vs $568.048 million estimate.
benzinga.com Cellebrite DI Sees Q3 Sales $145.000M-$148.000M vs $150.298M Est Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $145.000 million-$148.000 million vs $150.298 million analyst estimate.
benzinga.com Cellebrite DI Q2 Adj. EPS $0.11, Inline, Sales $131.138M Miss $131.874M Estimate Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.11 per share which met the analyst consensus estimate. This is a 8.33 percent decrease over earnings of $0.12 per share from the same…- benzinga.com DA Davidson Maintains Buy on Cellebrite DI, Raises Price Target to $22 DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $20 to $22.
- benzinga.com DA Davidson Initiates Coverage On Cellebrite DI with Buy Rating, Announces Price Target of $20 DA Davidson analyst Rudy Kessinger initiates coverage on Cellebrite DI (NASDAQ:CLBT) with a Buy rating and announces Price Target of $20.
benzinga.com Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $15 Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $18 to $15.- benzinga.com Cellebrite DI Q1 2026 Earnings Call Transcript
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Cellebrite Announces FedRAMP High Authorization For Its Cellebrite Government Cloud Platform Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that its Cellebrite Government…- benzinga.com 12 Information Technology Stocks Moving In Friday's After-Market Session
- benzinga.com Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $18 Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $18.
- benzinga.com Cellebrite DI Sees FY2026 Sales $565.000M-$571.000M vs $554.864M Est Cellebrite DI (NASDAQ:CLBT) sees FY2026 sales of $565.000 million-$571.000 million vs $554.864 million analyst estimate.
- benzinga.com Cellebrite DI Sees Q1 Sales $126.000M-$128.000M vs $130.637M Est Cellebrite DI (NASDAQ:CLBT) sees Q1 sales of $126.000 million-$128.000 million vs $130.637 million analyst estimate.
benzinga.com Cellebrite DI: Q4 Earnings Insights - benzinga.com Cellebrite DI Q4 Adj. EPS $0.14, Inline, Sales $128.821M Beat $126.556M Estimate Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.14 per share which met the analyst consensus estimate. This is a 40 percent increase over earnings of $0.10 per share from the same…
- benzinga.com Earnings Scheduled For February 11, 2026
benzinga.com Security Tech Check-In: Analyst Insights From 12 Companies Ahead Of The 'Quiet Period' Needham analysts met with 12 companies before quiet period. Ratings and price targets by analyst Mike Cikos.
benzinga.com These Fast-Rising Tech Stocks Are Surging in Growth Scores This Week 
benzinga.com JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $24 JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $23 to $24.
benzinga.com Lake Street Maintains Buy on Cellebrite DI, Raises Price Target to $23 Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $22 to $23.